Alexandria Hammond
Stock Analyst at Wolfe Research
(1.43)
# 2,793
Out of 4,667 analysts
13
Total ratings
22.22%
Success rate
-7.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $743.35 | +54.71% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $24.94 | +0.24% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $36.94 | +8.28% | 1 | Nov 15, 2024 | |
| MRK Merck & Co. | Initiates: Peer Perform | n/a | $97.44 | - | 1 | Nov 15, 2024 | |
| LLY Eli Lilly | Initiates: Outperform | $1,000 | $753.41 | +32.73% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $153.11 | +24.09% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $88.63 | +24.11% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $57.88 | - | 1 | Nov 15, 2024 | |
| BIIB Biogen | Initiates: Peer Perform | n/a | $156.00 | - | 1 | Nov 15, 2024 | |
| ABBV AbbVie | Initiates: Outperform | $205 | $167.76 | +22.20% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $30 | $30.64 | -2.07% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $150 | $317.09 | -52.69% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $30 | $7.98 | +275.94% | 1 | Apr 22, 2024 |
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $743.35
Upside: +54.71%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $24.94
Upside: +0.24%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $36.94
Upside: +8.28%
Merck & Co.
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $97.44
Upside: -
Eli Lilly
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $753.41
Upside: +32.73%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $153.11
Upside: +24.09%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $88.63
Upside: +24.11%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $57.88
Upside: -
Biogen
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $156.00
Upside: -
AbbVie
Nov 15, 2024
Initiates: Outperform
Price Target: $205
Current: $167.76
Upside: +22.20%
Apr 22, 2024
Reinstates: Neutral
Price Target: $30
Current: $30.64
Upside: -2.07%
Apr 22, 2024
Initiates: Underperform
Price Target: $150
Current: $317.09
Upside: -52.69%
Apr 22, 2024
Assumes: Buy
Price Target: $30
Current: $7.98
Upside: +275.94%